

Xience Bests Taxus in Target-Lesion Failure

BY MARY ANN MOON

FROM THE NEW ENGLAND JOURNAL OF
MEDICINE

Everolimus-eluting coronary stents produced a 38% relative reduction in the 1-year rate of target-lesion failure and a 45% relative reduction in target-lesion revascularization, compared with paclitaxel-eluting stents, according to randomized study.

In what the researchers described as the only clinical trial to date that was large enough to establish the superiority of one drug-eluting stent over another, the primary end point of target-lesion failure 1 year after percutaneous coronary intervention was 4.2% with everolimus-eluting stents, compared with 6.8% with paclitaxel-eluting stents, a significant difference.

The everolimus-eluting stent (Xience V, Abbott Vascular) also was superior with respect to the secondary end point of ischemia-driven target-lesion revascular-

Target-lesion failure at 1 year was 4.2% with the everolimus-eluting stent, compared with 6.8% with the paclitaxel-eluting stent. Rates of all-cause and cardiac death did not differ.

ization at 1 year, with a 2.5% rate of this outcome, compared with a significantly higher 4.6% rate for the paclitaxel-eluting stent (Taxus Express, Boston Scientific), said Dr. Gregg W. Stone of Columbia University, New York, and his associates in the Abbott-sponsored SPIRIT IV study.

However, the rates of cardiac death and of death from all causes were not significantly different between the two stents. This may be due in part to the low mortality in both groups after just 1 year. Longer follow-up "will determine whether these differences are durable or increase over time," the investigators said.

In addition, the everolimus-eluting stent did not show superiority in patients with diabetes—a major subgroup that accounts for a significant portion of stent procedures, they noted.

Dr. Stone and his colleagues compared the two devices in 3,687 patients, including 1,185 with diabetes, who underwent PCI at 66 U.S. medical centers in 2006-2008. These study subjects had up to three untreated coronary artery lesions that were as long as 28 mm, in vessels with a diameter of 2.5-3.75 mm.

The subjects were randomly assigned to receive everolimus-eluting stents (2,458 patients) or paclitaxel-eluting stents (1,229 patients) and were followed for 1 year.

The everolimus-eluting stent was superior regarding target-lesion failure and ischemia-driven target lesion revascularization; it was noninferior to the paclitaxel-eluting stent in the secondary end point of cardiac death or target-vessel myocardial infarction.

The everolimus-eluting stent also was

superior in the secondary end point of preventing stent thrombosis, with a 1-year rate of 0.85%, compared with a 1.10% rate for the paclitaxel-eluting stent group. This represents a relative reduction of 75%, Dr. Stone and his associates wrote (N. Engl. J. Med. 2010; 362:1663-74).

These findings were consistent across 11 subgroups of patients, regardless of patient symptoms or smoking, hyper-

tension, or cholesterol status; the number of lesions treated; which coronary vessels were involved; and the dimensions of the lesions or the vessels.

The sole exception was the large subgroup of diabetic patients, in whom there were no significant differences in outcomes between the two stents. A discrepancy in outcomes has been reported previously for diabetic patients receiving stents, and "suggests that the

mechanisms of restenosis or the response to antiproliferative agents may vary in patients with insulin resistance or deficiency," the researchers noted.

The SPIRIT IV trial was sponsored by Abbott Vascular. Dr. Stone reported ties to Abbott, Boston Scientific, Osprey Medical, InfraRedx, Reva Medical, Merck, CoreValve, St. Jude Medical, Edwards, and numerous other pharmaceutical and device companies. ■

Don't let **IMAGING REIMBURSEMENT CUTS** ruin your practice.
We will reduce your nuclear lab costs by 20% to 50%...**IMMEDIATELY!**

"Award winning proven solutions for reducing costs and increasing revenues associated with in-office Nuclear testing."

-DotMed News 2009

"Our office manager heard about UND from the ACC, so we called. They were able to lower our costs and we are now saving at least \$100,000 annually. We only wish we found them sooner!"

-Dr. Robert Dover, MD,
Cardiologist, Aventura FL

PROVEN SOLUTIONS to drastically REDUCE COSTS and increase revenue associated with your NUCLEAR LAB!

(877) 5-DIAGNOSTICS www.NuclearStressTest.net

UNDSmartLab™: For practices already offering in office Diagnostics - but want to reduce costs! UND will...

- ✓ Conduct a FREE assessment calculating the practice's current costs of diagnostic operations
- ✓ Reduce the practice's current operational costs by 20-50% ...GURANTEED!
- ✓ Assume all responsibilities with regards to testing (tech pay, isotopes, etc.)

UNDCompleteLab™: Great option for practices who thought they couldn't afford in office diagnostics! Identical to SmartLab but includes all necessary cameras & equipment. UND will...

- ✓ Obtain all necessary licensing for practice
- ✓ Provide all diagnostic testing equipment
- ✓ Assume all responsibilities with regards to testing (tech pay, isotopes, etc.)



**University
Nuclear & Diagnostics**
Complete In Office Diagnostic And Outsourcing Services

10396 SR 84, Suite 104 • Davie, Florida 33324 | USA
Toll Free (877) 5-DIAGNOSTICS (877) 534-2466
Fax (866) 221-7221 www.NuclearStressTest.net